- Home
- CRDF vs GCO Comparison
CRDF vs GCO Comparison
Compare CRDF & GCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- GCO
- Stock Information
- Founded
- CRDF 1999
- GCO 1924
- Country
- CRDF United States
- GCO United States
- Employees
- CRDF N/A
- GCO N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- GCO Clothing/Shoe/Accessory Stores
- Sector
- CRDF Health Care
- GCO Consumer Discretionary
- Exchange
- CRDF Nasdaq
- GCO Nasdaq
- Market Cap
- CRDF 233.5M
- GCO 212.2M
- IPO Year
- CRDF N/A
- GCO N/A
- Fundamental
- Price
- CRDF $2.64
- GCO $23.69
- Analyst Decision
- CRDF Strong Buy
- GCO Hold
- Analyst Count
- CRDF 6
- GCO 2
- Target Price
- CRDF $11.92
- GCO $24.50
- AVG Volume (30 Days)
- CRDF 3.0M
- GCO 180.1K
- Earning Date
- CRDF 07-29-2025
- GCO 09-05-2025
- Dividend Yield
- CRDF N/A
- GCO N/A
- EPS Growth
- CRDF N/A
- GCO N/A
- EPS
- CRDF N/A
- GCO N/A
- Revenue
- CRDF $545,000.00
- GCO $2,341,438,000.00
- Revenue This Year
- CRDF N/A
- GCO $2.53
- Revenue Next Year
- CRDF N/A
- GCO $2.01
- P/E Ratio
- CRDF N/A
- GCO N/A
- Revenue Growth
- CRDF N/A
- GCO 1.85
- 52 Week Low
- CRDF $2.01
- GCO $16.19
- 52 Week High
- CRDF $5.64
- GCO $44.80
- Technical
- Relative Strength Index (RSI)
- CRDF 34.68
- GCO 52.01
- Support Level
- CRDF $2.31
- GCO $24.05
- Resistance Level
- CRDF $4.52
- GCO $25.59
- Average True Range (ATR)
- CRDF 0.37
- GCO 1.08
- MACD
- CRDF -0.21
- GCO -0.05
- Stochastic Oscillator
- CRDF 14.67
- GCO 48.86
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About GCO Genesco Inc.
Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.